Home / Resources / Abzena Showcases Discovery and Developability Services at PEGS Europe 2019
Abzena Showcases Discovery and Developability Services at PEGS Europe 2019
Bespoke approach generates high affinity antibodies and selects lead candidates with the strongest chances of success in the clinic
Cambridge, UK, 18 November 2019 – Abzena is showcasing its Discovery and Developability Services, enabling biopharmaceutical companies to generate high affinity antibodies and select lead candidates with the highest chances of clinical success at the 11th Annual Protein & Antibody Engineering Summit (PEGS Europe) being held 18–22 November, on Booth #121 at the Lisbon Congress Centre, Lisbon, Portugal.
Abzena offers a Discovery Service that harnesses murine immunisation to generate antibodies with high affinity and desired functional properties. This is integrated with full Developability Services to assesses the fundamental characteristics of drug design – specificity, functionality, safety and manufacturability – to ensure the probability of identifying antibodies with appropriate therapeutic utility and maximise the chances of clinical success.
Campbell Bunce PhD, Chief Scientific Officer at Abzena, commented: “The development of biologics takes time, is expensive and subject to safety, functionality, stability and scalability liabilities. Having worked with hundreds of drug candidates, Abzena’s Discovery and Developability Services offer a defined approach that applies our expertise to guide the discovery and selection of the best drug candidates and reduce the risks that can significantly impact the time and cost typically associated with biopharmaceutical R&D.”
“Maximising the chances of therapeutic utility and clinical success drives our Discovery and Developability Services: from providing custom strategies for generating high affinity antibodies, to our Developability Service for selecting lead candidates and identifying measures that will mitigate risks,” added Rob Holgate PhD, Senior Director of Protein Engineering at Abzena.
Abzena provides the most complete set of solutions in integrated early discovery to mid-phase biotherapeutic and ADC drug development services in the pharmaceutical industry. The company maintains resources around the world, with facilities in the US and UK. Abzena is partnered with Welsh, Carson, Anderson & Stowe, one of the world’s leading private equity investors. For more information, please see www.abzena.com.